Table 3.

Multivariable-adjusted matched odds ratios (ORs) and 95% confidence intervals (CIs) of prostate cancer by Trichomonas vaginalis serostatus in a nested case-control study of Caucasian and African-American men in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial, 1993–2001

	Caucasian							African-American
	Controls	Gleason 7 PCa		Gleason ≥8 or stage III/IV PCa		Global p-value1	P-value for heterogeneity1	Controls	Total PCa		Global p-value2
	N	N	OR (95% CI)1	N	OR (95% CI)1			N	N	OR (95% CI)2
Seronegative	777	405	1.00	443	1.00	-----	-----	280	158	1.00	-----
Seropositive	84	33	0.83 (0.53–1.30)	44	0.90 (0.59–1.37)	0.64	0.80	75	43	1.12 (0.72–1.73)	0.61
Seropositive3	84	33	0.87 (0.55–1.37)	44	0.89 (0.58–1.37)	0.73	0.93	75	43	1.12 (0.72–1.75)	0.61
Seropositive3,4	84	33	0.87 (0.55–1.37)	44	0.89 (0.58–1.38)	0.74	0.93	75	43	1.05 (0.67–1.65)	0.55
Seropositive3,4,5	84	33	0.87 (0.55–1.37)	44	0.90 (0.58–1.38)	0.74	0.92	75	43	1.06 (0.67–1.68)	0.79

PSA=prostate-specific antigen; STI=sexually transmitted infection.

¹Calculated by competing risks Cox proportional hazards regression with data augmentation.

²Calculated by conditional logistic regression.

³Adjusted for age (in 1-year categories), first degree family history of PCa, cigarette smoking status, and a history of gonorrhea in Caucasian men, and for age (in 1-year categories), alcohol intake, and histories of gonorrhea and syphilis in African-American men.

⁴Additionally adjusted for self-reported physician diagnosis or prior surgery for an enlarged prostate or benign prostatic hypertrophy, and for self-reported nocturia.

⁵Additionally adjusted for self-reported physician diagnosis of an inflamed prostate or prostatitis.